Anti lir 1 hp f1

Manufactured by Thermo Fisher Scientific

Sourced in United States

Anti-Lir-1 (HP-F1) is a laboratory equipment product. It serves as a core function, but a detailed unbiased description cannot be provided while maintaining conciseness.

Automatically generated - may contain errors

Lab products found in correlation

Anti nkg2a z199, by Beckman Coulter (3 mentions) Rituximab rituxan, by Genentech (2 mentions) Phenylarsine oxide, by Merck Group (1 mentions) Anti cd107a h4a3, by BioLegend (1 mentions) Human ab serum, by Atlanta Biologicals (1 mentions) Recombinant human ifn γ, by BioLegend (1 mentions) Live dead fixable dead cell stain kit, by Thermo Fisher Scientific (1 mentions) 7 aad, by BD (1 mentions) Annexin 5, by BD (1 mentions) Tunicamycin, by Merck Group (1 mentions) Glutamine, by Thermo Fisher Scientific (1 mentions) Streptavidin bv650, by BioLegend (1 mentions) Fetal bovine serum (fbs), by Merck Group (1 mentions) Annexin 5 and 7 aad, by BD (1 mentions)

3 protocols using anti lir 1 hp f1

Killer Cell Receptor Expression Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

anti-CD56 (B159), anti-CD56 (NCAM-1), anti-CD3 (UCHT1), anti-CD16 (3G8), anti-CD64 (10.1), IgG1 (MOPC21) from Becton Dickinson (BD, CA, USA). Anti-KIR2DL1/DS1 (EB6), anti-KIR2DL2/3/DS2 (GL183) and anti-NKG2A (Z199) from Beckman Coulter (CA, USA). The anti-CD107a (H4A3) from Biolegend (CA, USA). The anti-Lir-1 (HP-F1) from eBioscience (CA, USA). The anti-human IgG4 (HP6025) and Phenylarsine oxide from Sigma Aldrich. The FcγRI (10.1) blocking antibody from R&D Systems (MN, USA). IPH2101 from Innate Pharmaceuticals Inc. (France)/Bristol-Myers Squibb (NY, USA). Rituximab (Rituxan) from Genentech (CA, USA). Human AB serum from Atlanta Biologicals (GA, USA). Human recombinant IFN-γ from Biolegend and human recombinant IL-2 (Proleukin® (Aldesleukin)) from Chiron (CA, USA). Human IvIg (Gammagard) from Baxter International Inc. (IL, USA).

Carlsten M., Korde N., Kotecha R., Reger R., Bor S., Kazandjian D., Landgren O, & Childs R.W. (2016). Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK-cells in Patients with Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 22(21), 5211-5222.

+ Open protocol

+ Expand

Multiparametric Analysis of NK Cell Activation

Check if the same lab product or an alternative is used in the 5 most similar protocols

anti-CD56 (B159), anti-CD56 (NCAM-1), anti-CD3 (UCHT1), Brefeldin A, 7-AAD and Annexin V were from Becton Dickinson (BD) (CA, USA). Anti-KIR2DL1/DS1 (EB6), anti-KIR2DL2/3/DS2 (GL183) and anti-NKG2A (Z199) were from Beckman Coulter (CA, USA). The anti-CD107a (H4A3), KIR3DL1 (Dx9), HLA class I (W6/32), HLA-E (3D12), DR5 (MDS5-1) were from Biolegend. The anti-Lir-1 (HP-F1) was from eBioscience (CA, USA). The LIVE/DEAD Fixable Dead Cell Stain kit was from Invitrogen (CA, USA). Tunicamycin was from Sigma Aldrich. Bortezomib was from Millennium Pharmaceuticals (MA, USA). Cisplatin was from APP Pharmaceuticals, LLC (IL, USA).

Carlsten M., Namazi A., Reger R., Levy E., Berg M., St. Hilaire C, & Childs R.W. (2018). Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5. Oncoimmunology, 8(2), e1534664.

+ Open protocol

+ Expand

Characterization of NK Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The K562, MM.1S, and CD20⁺ 721.221 cell lines were obtained from ATCC and propagated in RPMI 1640 supplemented with 10% heat-inactivated FBS (Sigma-Aldrich) and 2 mM glutamine (Life Technologies). The following reagents were used: anti-CD56 (NCAM-1), anti-CD3 (UCHT1), anti-CD16 (3G8), anti-NKG2D (1D11), anti-TRAIL (RIK-2), anti-NKp30 (p30-15), anti-NKp46 (29A1.4), IgG1 (MOPC21), and Annexin V and 7-AAD from Becton Dickinson (BD); anti-KIR2DL1/DS1 (EB6), anti-KIR2DL2/3/DS2 (GL183), and anti-NKG2A (Z199) from Beckman Coulter; the anti-CD107a (H4A3), anti-KIR3DL1 (Dx9), anti-CD57 (HCD57), anti-2B4 (C1.7), anti-CD34 (581), anti-CCR7 (G043H7), IgG2a (MOPC-173), and BV650-streptavidin from Biolegend; the anti-Lir-1 (HP-F1) from eBioscience; the anti-NKG2C (134591) from R&D Systems; LIVE/DEAD viability marker from Life Technologies; biotinylated anti-KIR3DL2 (Dx31) from UCSF; rituximab (Rituxan) from Genentech; and off-the-shelf eGFP mRNA and custom-made CD34, CD16, and CCR7 mRNAs from TriLink Biotechnology.

Carlsten M., Levy E., Karambelkar A., Li L., Reger R., Berg M., Peshwa M.V, & Childs R.W. (2016). Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19. Frontiers in Immunology, 7, 105.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!